The uptake of GLP-1 has surged since 2022, mainly in US. Read our takeaways from the UBS Evidence Lab survey on key trends in GLP-1 consumer behaviour GLP-1s, also known as glucagon-like peptide 1, ...

New research shows GLP-1 receptor agonists may protect patients ... limited additional benefit against other cancers in this comparison. Nonetheless, there were no significant differences in ...

With sales of around $2.7 billion in 2015, Victoza has dominated the GLP-1 market despite competition from AstraZeneca. But Lyxumia’s sales in 2015 were miniscule in comparison, at $38 million ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development ...